BBS1 and Bardet-Biedl syndrome: Additionally, Setmelanotide has shown therapeutic efficacy in cases of chronic obesity caused by ciliopathic genetic syndromes, such as Bardet–Biedl syndrome (BBS), caused by a mutation in (BBS1-BBS22).